





Screening of Celiac Disease
eliac disease (CD) is a chronic,Cimmune-mediated disorder
caused by an intolerance to ingested
gluten present in some cereals such as
wheat, rye, and barley. CD develops in





































it has been estimated that it affects
approximately 1% of Caucasians.1,2
The diagnosis of CD is based on the
presence of intestinal symptoms
together with the evaluation of genetic
(HLA-DQ2þ and/or DQ8þ), serologic
(anti-endomysium and anti-
transglutaminase autoantibodies), and
histologic markers.3 It has been argued
that approximately 70% of CD cases are
not diagnosed properly as a result of
negative serologic results and the
complex interpretation of the histologic
findings in intestinal biopsy specimens,













P<.05 P<.01patients.4 Moreover, diagnostic endos-
copy is an expensive procedure that
involves sedation or anesthesia, and no
more than 1:7 people with the highest
HLA risk genotype are finally diagnosed
with CD.5 However, an early and proper
diagnosis of the disease is of great
importance to avoid extraintestinal
complications, including cardiovascular
and neurologic problems or the devel-
opment of certain types of cancer.
Thus, additional diagnostic tests, pref-
erentially tests that are cost effective
and noninvasive, are strictly
necessary.6Figure 1. Heatmaps of (A) the in-
flammatory biomarkers expressed in
small intestine and saliva (n [ 6) and
of the 8 selected genes in the (B)
small intestine or (C) saliva from
active celiac patients (n [ 18) and
controls (n [ 21). Expression values
were normalized against the average
expression of each gene. Differential
expression of the genes CXCL1 and
IL1B in the (D) small intestine and (E)
saliva samples from active celiac pa-
tients celiac disease (CD) (N ¼ 18) and
controls (Ctrl) (n ¼ 21). **P < .01; *P <
.05; þP < .1 by Student t test. (F)
Pearson correlation (r) of CXCL1 (grey
dots) and IL1B (black dots) expression
between small intestine and saliva
samples (n ¼ 39).



















































Figure 2. Receiver operating charac-
teristic (ROC) plot of the combinatory
logistic regression model including
gene expression and HLA genotype
in the (A) evaluation cohort (n [ 39)
and (C) confirmation cohort (N [
100). Comparison of the combinatory
logistic regression values between ce-
liac patients (celiac disease [CD]) and
controls (Ctrl) in the (B) evaluation
cohort (n ¼ 39) and (D) confirmation
cohort (n ¼ 100). **P < .01 by Student
t test.
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gastrointestinal system and it has been
suggested that it could resemble its
immunopathologic characteristics, be-
ing a much more accessible tissue for
CD diagnosis.7 Given that saliva is the
most accessible body fluid, it has been
broadly scrutinized for biomarkers of
noninvasive diagnosis of a wide range
of disorders, including inflammatory
bowel disease.8 Although some at-
tempts for CD screening in saliva have
been performed (ie, antibody detec-
tion),9 gene expression analyses of CD-
related inflammatory cytokines have
not been assessed in this fluid.
Considering that CD is highly
underdiagnosed and that actual tests
are expensive and invasive, our aim
was to analyze the expression of in-
flammatory genes in the intestine and
saliva of celiac patients and controls to
find salivary biomarkers that resemble
the status of the intestinal epithelium
and that could be used for diagnosis. In
addition, we wanted to leverage the
saliva collection to set up HLA geno-
typing in this fluid, strengthening thepredictive power of the gene expres-
sion signature.
To select potential biomarkers, we
quantified the expression of 92 inflam-
matory genes in intestinal and saliva
samples from 6 individuals (3 celiac
patients and 3 controls). Fourteen of
the genes tested were expressed in all
the samples, in both saliva and small
intestine (Figure 1A). The 8 inflamma-
tory genes with the highest and most
reproducible expression levels were
selected for subsequent analyses in in-
testinal and saliva samples from
another 18 celiac patients and 21 non-
celiac individuals. All genes were
expressed in the intestine, although in 3
of the saliva samples 1 to 3 genes could
not be detected (Figure 1B and C). To
evaluate if the inflammatory gene
expression in saliva resembles the sta-
tus of the celiac intestinal epithelia, we
compared gene expression between
celiac and non-celiac patients in both
tissues. We found that genes CXCL1 and
IL1B were up-regulated in CD biopsy
specimens (Figure 1D). Likewise, CXCL1
and IL1B presented increasedexpression in the saliva of patients
(Figure 1E). Correlation analyses be-
tween intestine and saliva showed a
statistically significant correlation be-
tween the levels of these genes in both
tissues (Figure 1F), suggesting that the
celiac-related gene expression changes
of the intestine can be assessed in
saliva. Investigating whether other in-
flammatory conditions of the gut or
mouth also present these or other al-
terations in saliva gene expression
would be of great interest.
Subsequently, we evaluated whether
these salivary biomarkers could have
clinical utility to differentiate between
CD patients and non-celiac controls in
the same sample set. Receiver opera-
ting characteristic curve analyses yiel-
ded area under the curve (AUC)
values greater than 0.7 for both genes
(Supplementary Figure 1A and B). In
addition, a logistic regression model was
built using the combination of both
biomarkers. The combinatory logistic
regression model yielded a receiver
operating characteristic plot AUC value
of 0.69 (Supplementary Figure 1C and
2021 Noninvasive Diagnosis for Celiac Disease 1513D). Finally, the addition of the HLA
genotyping (CD risk, HLA-DQ2/DQ8þ;
or nonrisk)10 in the same saliva sam-
ples improved all 3 models, giving a
0.84 AUC value (P < .01; 95% CI,
0.7064–0.9742) (Figure 2A and B), with
81% sensitivity and 67% specificity in
distinguishing celiac patients from non-
celiac individuals.
To validate if this model could be
useful for a noninvasive diagnosis of CD
we performed a blind analysis of 100
saliva samples of individuals who were
evaluated by the gastroenterologists as
potential celiac patients. We assigned a
disease/non-disease classification to
each patient based on the values of the
combined expression of the 2 bio-
markers plus the presence of the HLA
risk genotype. We correctly classified
73% of the individuals (Figure 2D) with
91% sensitivity and 51% specificity,
thus confirming the validity of the
technique for CD screening. If only those
patients being prediagnosed as celiac
using this model were subjected to
endoscopy and biopsy acquisition, we
would improve the positivity rate from
the actual 1:7 to 2:3.
Here we present a systematic study
profiling inflammatory markers in saliva
samples of CD patients, enhancing the
prospect of an important role for sali-
vary diagnostics in the detection of
gastrointestinal pathologies. Moreover,
we have used the same starting material
for both gene expression analyses and
HLA genotyping, limiting the collection
to a single noninvasive sample. We
found that the use of this combination
as a prediagnostic approach would
reduce the number of patients subjected
to endoscopy and biopsy acquisition
and improve the positivity rate, with the
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Patients and Study Design
This study was approved by the Basque
Country Clinical Research Ethics Board
(CEIC-E ref. PI2018007) and analyses
were performed after informed
consent was obtained from all subjects
or their parents. Celiac disease in
pediatric patients was diagnosed ac-
cording to the European Society of Pe-
diatric Gastroenterology Hematology
and Nutrition criteria in force at
the time of recruitment, including
antigliadin, anti-endomysium, and
anti–transglutaminase antibody de-
terminations, as well as a confirmatory
small-bowel biopsy, and analyses were
performed after informed consent was
obtained from all subjects or their par-
ents. All newly diagnosed adult CD pa-
tients had increased transglutaminase
antibody titers and showed character-
istic small intestinal histopathologic
abnormalities, including villous atro-
phy, crypt hyperplasia, and intra-
epithelial lymphocytosis. Healthy
control individuals were matched for
age and sex, none of them suffered from
any immunologic disorder. The infor-
mation on individual characteristics,
such as age and sex, and clinical char-
acteristics, is presented in
Supplementary Table 1.RNA Extraction
For intestinal biopsy samples RNA
extraction was performed using the
NucleoSpin RNA Kit (740984.50;
Macherey Nagel, Düren, Germany).
Saliva samples were collected with
DNA/RNA Shield collection tube with
swab (R1107-E; Zymo Research,
Irvine, CA) after confirming that pa-
tients did not eat at least 2 hours
before the sample collection. RNA was
extracted from 500 uL saliva superna-
tant using the Direct-zol RNA Miniprep
kit with TRI reagent (R2053; Zymo
Research).TaqMan Low-Density Arrays
A total of 125 ng RNA was used for the
retrotranscription reaction using the
iScript cDNA Synthesis Kit (1708890;
Bio-Rad, Hercules, CA). Samples were
prepared and mixed with Gene
Expression Master Mix (4369016;
ThermoFisher Applied Biosystems,
Foster City, CA) following the manu-
facturer’s instruction to load them in
the TaqMan Low Density Arrays
(Applied Biosystems). The RPLP0 gene
was used as endogenous control both
in biopsy specimens and saliva samples.
Reactions were run in the 7900HT Fast
Real-Time Polymerase Chain Reaction
System using the TaqMan Low-Density
Arrays Block Module (Applied Bio-
systems). All quantitative polymerase
chain reaction (PCR) measurements
were performed in triplicate and
expression levels were analyzed using
the 2–delta delta Ct method. All Taq-
Man Gene expression Assays loaded in
the TaqMan low-density arrays are lis-
ted in Supplementary Table 2.
Reverse-Transcription
Quantitative PCR
For the validation of the biomarkers,
50 ng RNA extracted from saliva was
used for One Step Reverse-
Transcription Quantitative PCR using
the Quantitec Probe Reverse-
Transcription-PCR kit (204443; Qia-
gen, Hilden, Germany). The RPLP0 gene
was used as endogenous control. Re-
actions were run in a Bio-Rad CFX384.
All quantitative PCR measurements
were performed in duplicate and
expression levels were analyzed using
the 2–DDCt method. The previously




For each biomarker, the receiver oper-
ating characteristic curve was con-
structed and the AUC value was
computed by numeric integration of the
receiver operating characteristic curve.The logistic regression method was
used for predicting the validity of the
biomarker. For this model, the pre-
dicted probability for each subject was
obtained and alsowas used to construct
a receiver operating characteristic
curve. The standard error of the AUC
and the 95% CI for the receiver oper-
ating characteristic curves were
computed and the sensitivity and spec-
ificity for each biomarker and for the
biomarker combination were estimated
by identifying the cut-off point of the
predicted probability that yielded the
highest sum of sensitivity and
specificity.Allelic Discrimination for HLA
Genotyping
DNA extraction was performed using
50 uL saliva supernatant by an
isopropanol–ethanol precipitation-
based method. 30uL of isopropanol
(I9516-500ML; Sigma-Aldrich, St.
Louis, MO) were added to the saliva
sample for nucleic acid precipitation
followed by cold centrifugation at
15,000g for 15 minutes. After
washing the pellet with 70% ethanol
(ET00041000; Scharlab S.L., Sentme-
nat, Barcelona, Spain) at room tem-
perature, the DNA fraction was
precipitated by cold centrifugation at
15,000 g for 10 minutes. The pellet
was air-dried and redissolved in
DNase- and RNase-free water. HLA-
DQ2 genotyping was performed us-
ing the genotyping assay for
rs2187668 single-nucleotide poly-
morphism and TaqMan Genotyping
Master Mix (4371353; Applied Bio-
systems, Foster City, CA). HLA-DQ8
genotyping was performed using the
genotyping assay for rs7454108
single-nucleotide polymorphism and
rhAmp Genotyping Master Mix
(1076014; IDT, Irvine, CA), with
rhAmp Reporter Mix with reference
(1076020; IDT). Reactions were run
in a Bio-Rad CFX384 and allelic
discrimination was performed using


























ROC curve: CXCL1 saliva
AUC= 0.72
p<0.05




























B Supplementary Figure 1.Receiver operating character-
istic (ROC) plot of the individual
gene expression values of (A)
CXCL1 and (B) IL1B in the eval-
uation cohort (n [ 39). (C) ROC
plot of the combinatory logistic
regression model of the expres-
sion of both genes in the evalua-
tion cohort (n ¼ 39). (D)
Comparison of the combinatory
logistic regression values using
gene expression between celiac
disease patients (CD) and controls
(Ctrl) in the evaluation cohort (n ¼
39). **P < .01 based on an un-
paired Student t test. AUC, area
under the curve.
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